274 related articles for article (PubMed ID: 24947881)
1. Antititin antibody in early- and late-onset myasthenia gravis.
Szczudlik P; Szyluk B; Lipowska M; Ryniewicz B; Kubiszewska J; Dutkiewicz M; Gilhus NE; Kostera-Pruszczyk A
Acta Neurol Scand; 2014 Oct; 130(4):229-33. PubMed ID: 24947881
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis.
Klein R; Marx A; Ströbel P; Schalke B; Nix W; Willcox N
Hum Immunol; 2013 Sep; 74(9):1184-93. PubMed ID: 23792059
[TBL] [Abstract][Full Text] [Related]
3. Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.
Cordts I; Bodart N; Hartmann K; Karagiorgou K; Tzartos JS; Mei L; Reimann J; Van Damme P; Rivner MH; Vigneron A; Weis J; Schulz JB; Tzartos SJ; Claeys KG
J Neurol; 2017 Jun; 264(6):1193-1203. PubMed ID: 28516329
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies in acquired myasthenia gravis: Clinical phenotype and immunological correlation.
Nagappa M; Mahadevan A; Gangadhar Y; Patil SA; Bokolia S; Bindu PS; Sinha S; Taly AB
Acta Neurol Scand; 2019 May; 139(5):428-437. PubMed ID: 30693486
[TBL] [Abstract][Full Text] [Related]
5. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.
Romi F; Skeie GO; Aarli JA; Gilhus NE
Arch Neurol; 2000 Nov; 57(11):1596-600. PubMed ID: 11074791
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of late-onset myasthenia gravis.
Zivković SA; Clemens PR; Lacomis D
J Neurol; 2012 Oct; 259(10):2167-71. PubMed ID: 22476514
[TBL] [Abstract][Full Text] [Related]
7. Classification of myasthenia gravis based on autoantibody status.
Suzuki S; Utsugisawa K; Nagane Y; Satoh T; Terayama Y; Suzuki N; Kuwana M
Arch Neurol; 2007 Aug; 64(8):1121-4. PubMed ID: 17698702
[TBL] [Abstract][Full Text] [Related]
8. Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis.
Shelton GD; Skeie GO; Kass PH; Aarli JA
Vet Immunol Immunopathol; 2001 Jan; 78(1):97-105. PubMed ID: 11182151
[TBL] [Abstract][Full Text] [Related]
9. Clinical differences of early and late-onset myasthenia gravis in 985 patients.
Fan L; Ma S; Yang Y; Yan Z; Li J; Li Z
Neurol Res; 2019 Jan; 41(1):45-51. PubMed ID: 30311866
[No Abstract] [Full Text] [Related]
10. Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis?
Choi Decroos E; Hobson-Webb LD; Juel VC; Massey JM; Sanders DB
Muscle Nerve; 2014 Jan; 49(1):30-4. PubMed ID: 23625360
[TBL] [Abstract][Full Text] [Related]
11. The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis.
Chen XJ; Qiao J; Xiao BG; Lu CZ
J Neurol; 2004 Aug; 251(8):1006-11. PubMed ID: 15316806
[TBL] [Abstract][Full Text] [Related]
12. High anti-EBNA-1 IgG levels are associated with early-onset myasthenia gravis.
Csuka D; Banati M; Rozsa C; Füst G; Illes Z
Eur J Neurol; 2012 Jun; 19(6):842-6. PubMed ID: 22221650
[TBL] [Abstract][Full Text] [Related]
13. Thymic expression of the main immunogenic region of titin in thymomatous myasthenia gravis.
He ZF; Lv W; Qiao J; Chen ZM; Pang LW; Chen XJ
J Int Med Res; 2010; 38(4):1324-32. PubMed ID: 20926005
[TBL] [Abstract][Full Text] [Related]
14. Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome.
Yildiz Celik S; Durmus H; Yilmaz V; Saruhan Direskeneli G; Gulsen Parman Y; Serdaroglu Oflazer P; Deymeer F
Acta Neurol Belg; 2020 Feb; 120(1):133-140. PubMed ID: 31811563
[TBL] [Abstract][Full Text] [Related]
15. A case of late-onset, thymoma-associated myasthenia gravis with ryanodine receptor and titin antibodies and concomitant granulomatous myositis.
Stefanou MI; Komorowski L; Kade S; Bornemann A; Ziemann U; Synofzik M
BMC Neurol; 2016 Sep; 16(1):172. PubMed ID: 27623618
[TBL] [Abstract][Full Text] [Related]
16. Late-onset myasthenia gravis is predisposed to become generalized in the elderly.
Sakai W; Matsui N; Ishida M; Furukawa T; Miyazaki Y; Fujita K; Miyamoto R; Yamamoto N; Sako W; Sato K; Kondo K; Nishida Y; Mitsui T; Izumi Y; Kaji R
eNeurologicalSci; 2016 Mar; 2():17-20. PubMed ID: 29473057
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to skeletal muscle in myasthenia gravis. Part 2. Prevalence in non-thymoma patients.
Kuks JB; Limburg PC; Horst G; Oosterhuis HJ
J Neurol Sci; 1993 Dec; 120(1):78-81. PubMed ID: 8289082
[TBL] [Abstract][Full Text] [Related]
18. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients.
Yamamoto AM; Gajdos P; Eymard B; Tranchant C; Warter JM; Gomez L; Bourquin C; Bach JF; Garchon HJ
Arch Neurol; 2001 Jun; 58(6):885-90. PubMed ID: 11405802
[TBL] [Abstract][Full Text] [Related]
19. Muscle autoantibodies in subgroups of myasthenia gravis patients.
Romi F; Skeie GO; Aarli JA; Gilhus NE
J Neurol; 2000 May; 247(5):369-75. PubMed ID: 10896269
[TBL] [Abstract][Full Text] [Related]
20. Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis.
Spagni G; Todi L; Monte G; Valentini M; Di Sante G; Damato V; Marino M; Evoli A; Lantieri F; Provenzano C
Ann Clin Transl Neurol; 2021 Mar; 8(3):656-665. PubMed ID: 33547763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
